Myeloid growth factors

Myeloid growth factors

Mechanism of Action

FILGRASTIM (G-CSF) regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation, differentiation and functional activation
- also mobilizes hematopoietic stem cells, increasing their concentration in peripheral blood
  - led to the use of peripheral blood stem cells (PBSCs) rather than bone marrow stem cells for transplantation

SAGRAMOSTIM (GM-CSF) stimulates myelopoiesis generally, and neutrophils and monocytes specifically

Pharmacokinetics

PEGFILGRASTIM is a conjugation product of filgrastim with polyethylene glycol
- much long half-life
- injected once per chemotherapy cycle, instead of daily for several days

Therapeutic Uses

cancer chemotherapy-induced neutropenia (esp. FILGRASTIM)
- esp. during autologous stem cell transplantation following high-dose chemotherapy
- objective is to prevent systemic infection (neutrophils are the 1st line of defence against infection)

congenital neutropenia, cyclic neutropenia, myelodysplasia, and aplastic anemia

Side effects

FILGRASTIM/PEGFILGRASTIM

LIFE-THREATENING:

	SERIOUS	INNOCUOUS
COMMON		mild/moderate bone pain (F/P better tolerated than S)
RARE	allergic reactions splenic rupture

SARGRAMOSTIM

LIFE-THREATENING:

	SERIOUS	INNOCUOUS
COMMON	capillary leak syndrome (peripheral edema, pleural or pericardial effusions) – some patients are extremely sensitive	moderate/severe bone pain (F/P better tolerated than S) fever malaise arthralgias myalgias
RARE	allergic reactions

Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 27-apr-15 1:11 PM